Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc

Like
Comment
Favorite

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc

THOMSON REUTERS01-23

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

06:45
Brilliant Future Ab - Through Partnership Avonova Will Be Able to Include Co's Measurement Tools as Part of Its Customer Offering
06:45
Brilliant Future Ab - Framework Agreement Extends Over Three Years Without Volume Guarantees, Can Then Be Extended for Three Years at a Time
06:45
Brilliant Future Ab - Brilliant Future Enters Strategic Partnership With Avonova
06:45
Clariane: Governance Evolution - Mrs Sylvia Metayer, Independent Director, Appointed Chairwoman of the Board of Directors With Effect From May 14TH, 2025
06:43
the Nomination Committee of Husqvarna Ab (Publ) Proposes Changes to the Board of Directors to Be Elected at the 2025 AGM

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2505405868?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-23 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505405868","market":"us","top_or_hot":-1,"title":"Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc","media":"THOMSON REUTERS","content":"<html><body><p>Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc</p></body></html>","source":"reuters_en_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-23 13:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8YZ3Q0:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8YZ3Q0:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA8YZ3Q0:1","article_id":"2505405868","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505405868","pubTimestamp":1737610044,"columns":[],"sourceInfo":{"source_id":"reuters_en_live","name":"Thomson Reuters"},"weMediaInfo":null,"summary":"Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With","collect":0,"end_time":0,"defaultTopTitle":"refinitiv.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"科伦生物产品塔吉坦利单抗第二适应症获批上市联合顺铂和吉西他滨一线治疗复发或转移性鼻咽癌患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Patients With Recurrent or Metastatic Npc","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}